Explore more publications!
St. Vincent & Grenadines Health Press
Got News to Share?

St. Vincent & Grenadines Health Press: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on St. Vincent & Grenadines Health Press.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 3, 2025

Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners
December 3, 2025

Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners

Indeterminate GlobeNewswire
Wake Radiology UNC Health Rex Announces the Retirement of Body Imaging Radiologist Dr. Imre Gaal Jr.
December 3, 2025

Wake Radiology UNC Health Rex Announces the Retirement of Body Imaging Radiologist Dr. Imre Gaal Jr.

Indeterminate GlobeNewswire
Nika Pharmaceuticals, Inc. (NIKA) Progress Update
December 3, 2025

Nika Pharmaceuticals, Inc. (NIKA) Progress Update

Indeterminate GlobeNewswire
ENT & Allergy Associates Expands Network to Texas by Partnering with Houston ENT & Allergy
December 3, 2025

ENT & Allergy Associates Expands Network to Texas by Partnering with Houston ENT & Allergy

Indeterminate GlobeNewswire
Carl H. Sharperson III Joins MATTER Board of Directors
December 3, 2025

Carl H. Sharperson III Joins MATTER Board of Directors

Indeterminate GlobeNewswire
4D Path’s Physics-Inspired QPOR™ Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial
December 3, 2025

4D Path’s Physics-Inspired QPOR™ Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial

Indeterminate GlobeNewswire
NMDP Hires New Philanthropic Leader to Accelerate Financial Giving and Research
December 3, 2025

NMDP Hires New Philanthropic Leader to Accelerate Financial Giving and Research

Indeterminate GlobeNewswire
Elevar Therapeutics Announces Publication of CARES-310 Study Final Analysis in The Lancet Oncology
December 3, 2025

Elevar Therapeutics Announces Publication of CARES-310 Study Final Analysis in The Lancet Oncology

Indeterminate GlobeNewswire
BetaGlue Therapeutics erweitert klinische Studie in Italien nach Genehmigung vom italienischen Gesundheitsministerium zur Durchführung einer klinischen Studie bei nicht resezierbarem, lokal fortgeschrittenem Bauchspeicheldrüsenkrebs (uLA-PDAC)
December 3, 2025

BetaGlue Therapeutics erweitert klinische Studie in Italien nach Genehmigung vom italienischen Gesundheitsministerium zur Durchführung einer klinischen Studie bei nicht resezierbarem, lokal fortgeschrittenem Bauchspeicheldrüsenkrebs (uLA-PDAC)

Indeterminate GlobeNewswire
BetaGlue Therapeutics étend son essai clinique en Italie après avoir obtenu l’autorisation du ministère de la Santé italien pour mener son étude clinique sur le cancer du pancréas localement avancé non résécable (uLA-PDAC)
December 3, 2025

BetaGlue Therapeutics étend son essai clinique en Italie après avoir obtenu l’autorisation du ministère de la Santé italien pour mener son étude clinique sur le cancer du pancréas localement avancé non résécable (uLA-PDAC)

Indeterminate GlobeNewswire
Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product
December 3, 2025

Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product

Indeterminate GlobeNewswire
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum
December 3, 2025

Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum

Indeterminate GlobeNewswire
BioNTech erfüllt Mindestannahmebedingungen im Rahmen des Umtauschangebots für CureVac-Aktien
December 3, 2025

BioNTech erfüllt Mindestannahmebedingungen im Rahmen des Umtauschangebots für CureVac-Aktien

Indeterminate GlobeNewswire
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
December 3, 2025

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

Indeterminate GlobeNewswire
Wesley Pharmaceuticals Unveils First Product, Zinc Sulfate, Revolutionizing Wellness Solutions
December 3, 2025

Wesley Pharmaceuticals Unveils First Product, Zinc Sulfate, Revolutionizing Wellness Solutions

Indeterminate GlobeNewswire
Brevard Health Alliance Improves Hypertension Control with RPM Program Utilizing Rimidi's Platform and Connected Devices
December 3, 2025

Brevard Health Alliance Improves Hypertension Control with RPM Program Utilizing Rimidi's Platform and Connected Devices

Indeterminate GlobeNewswire
Aeroflow Urology Donates $30,000 to Support Family-Centered Care
December 3, 2025

Aeroflow Urology Donates $30,000 to Support Family-Centered Care

Indeterminate GlobeNewswire
Muscular Dystrophy Association Announces nearly $2 Million in Collaborative Research Grants Advancing Treatments Across Multiple Neuromuscular Diseases
December 3, 2025

Muscular Dystrophy Association Announces nearly $2 Million in Collaborative Research Grants Advancing Treatments Across Multiple Neuromuscular Diseases

Indeterminate GlobeNewswire
Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech Space
December 3, 2025

Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech Space

Indeterminate GlobeNewswire
Oncotelic and Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing
December 3, 2025

Oncotelic and Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions